L002 is a potent, cell-permeable, reversible, and selective inhibitor of the acetyltransferase p300 (KAT3B), with potential applications in the study of hypertension-induced cardiac hypertrophy and fibrosis. It inhibits histone acetylation, p53 acetylation, and STAT3 activation by competitively binding to the acetyl-CoA pocket of the p300 catalytic domain. In vivo, L002 (administered via intraperitoneal injection at 20 μg/g body weight every third day for 2 weeks) reverses hypertension-induced cardiac hypertrophy and fibrosis in mice, and reduces perivascular and interstitial collagen deposition in the myocardium.